[Diabetes and heart failure, a fatal association].
The prevalence of heart failure and diabetes are both increasing: 25 to 30% of patients with heart failure suffer from diabetes, and the latter aggravates heart failure. The presence of macro- or micro-angiopathy, cardiac neuropathy or renal failure worsens the clinical pattern and disturbs treatment strategies. Doppler-echocardiography and the dosage of BNP can probably help to detect and consequently to treat prematurely heart failure in the diabetic patient. The usual treatments in heart failure have similar or lower efficacy in the diabetic patient, and treatment intolerance is frequent. Treatments used for diabetes can be handled with difficulty in case of heart failure (metformin, glitazones). In the future, it is therefore extremely important: 1--to prevent the occurrence of diabetes in patients with glucose intolerance; 2--in diabetic patients, to prematurely detect cardiac dysfunction and optimally control diabetes, in order to avoid its occurrence; 3--and finally, in diabetic patients with heart failure, to optimize the medical treatment, in order that these patients have similar benefits compared to non-diabetic patients with heart failure. The ACE-inhibitors and angiotensin-2 antagonists seem to have an important role. Treatments breaking the glycation bridges, as well as statins, appear as interesting therapeutic options. Finally, the exact role of myocardial revascularization, either by angioplasty or surgery, might probably be important.
Cohen-Solal
A
A
Département de Cardiologie, hôpital Lariboisière, 2 rue Ambroise-Paré, 75010 Paris.
Logeart
D
D
D000804:Angiotensin II / Q000037:antagonists & inhibitors; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002303:Cardiac Output, Low / Q000150:complications* / Q000175:diagnosis; D048909:Diabetes Complications / Q000517:prevention & control; D003920:Diabetes Mellitus / Q000517:prevention & control; D015150:Echocardiography, Doppler; D018149:Glucose Intolerance / Q000517:prevention & control; D006801:Humans; D020097:Natriuretic Peptide, Brain
D000806:Angiotensin-Converting Enzyme Inhibitors; D000804:Angiotensin II; D020097:Natriuretic Peptide, Brain